Specifically, Tekturna was associated with an increased risk of non-fatal stroke, renal complications, hyperkalemia, and hypotension .

FORBES: ALTITUDE Study of Aliskiren Terminated Early by Novartis

Chelsea Therapeutics soared 1.47, or 61%, to 3.88, after the biopharmaceutical company said a Food and Drug Administration committee recommended the approval of its treatment for neurogenic orthostatic hypotension.

WSJ: S&P 500 Notches Highest Close Since June 2008

The action was based on the recommendation of the independent Data Monitoring Committee (DMC), after it found an increased risk for non-fatal stroke, renal complications, hyperkalemia, and hypotension in patients taking aliskiren after 18-24 months.

FORBES: ALTITUDE Study of Aliskiren Terminated Early by Novartis